Australia's most trusted
source of pharma news
Sunday, 05 October 2025
Posted 1 October 2025 AM
Pfizer has started a Phase 3 clinical trial into a potential first-in-class medicine for breast cancer based on research by Monash University and the Cancer Therapeutics Cooperative Research Centre (CTx).
The new therapy, PF-07248144, is being studied as a treatment in adults with HR+, HER2- advanced or metastatic breast cancer whose disease has progressed following prior treatments.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.